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1. Introduction 
Acute pulmonary embolism (PE) is an under-diagnosed but potentially fatal condition. This 
condition presents with a wide clinical spectrum, from asymptomatic small PE to life-
threatening one causing cardiogenic shock.  
Depending on the estimated risk of an adverse outcome, treatment with thrombolysis or 
embolectomy may be indicated in high-risk individuals. Conversely, early hospital 
discharge or even home treatment with anti-coagulation may be considered in low risk PE. 
Thus, a systematic approach to risk stratification is essential in guiding the management of 
patients diagnosed with acute PE. Evidence-based prognostic tools such as clinical scores, 
echocardiography, computed tomography scans, and cardiac biomarkers will be discussed.  
2. Hemodynamic consequences of acute pulmonary embolism 
Anatomically massive PE has been defined as having more than 50% obstruction of the 
pulmonary vasculature or the occlusion of two or more lobar arteries (Urokinase Pulmonary 
Embolism Study Group, 1970). In a unique situation, a large embolus may lodge at the 
bifurcation of the main pulmonary artery, i.e. saddle embolus. Although it was once regarded 
as a severe form of PE, a saddle PE shares a similar clinical course with a non-saddle PE, and 
low in-hospital mortality (Pruszczyk et al., 2003; Kaczyńska et al., 2005; Ryu et al., 2007).  
An anatomically massive PE in a patient with adequate cardiopulmonary reserve and  
a submassive PE in a patient with poor reserve may manifest similar hemodynamic 
outcomes. The hemodynamic response to an acute PE depends not only the size of  
the embolus and the degree of pulmonary vasculature obstruction, but also on the 
physiologic reaction to the neurohumoral factors released and the underlying 
cardiopulmonary status of the patient.  
Normally, the RV faces low resistance as it empties into a low-pressure system of the 
pulmonary vasculature. In acute PE, both mechanical obstruction and hypoxic 
vasoconstriction increase pulmonary vascular resistance, and this initiates a series of 
hemodynamic derangements leading to RV dysfunction (Figure 1). The release of humoral 
factors, such as serotonin from platelets, thrombin from plasma and histamine from tissue 
also contribute to pulmonary artery vasoconstriction. As a consequence of the elevated 
pulmonary resistance, the highly compliant RV dilates acutely.  
Initially, compensatory maintenance of cardiac output is achieved by catecholamine-driven 
tachycardia and vasoconstriction. The left atrial contraction also contributes more than usual to 
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left ventricular filling. Eventually, with persistent pressure overload and wall stress, RV 
systolic function begins to fall. Cardiac output is decreased further by impaired distensibility 
of the left ventricle (LV) from the leftward shift and flattening of the interventricular septum 
during systole/early diastole, and impaired LV filling during diastole.  
Myocardial ischemia also worsens RV function by increased oxygen demands due to 
elevated wall stress and decreased oxygen supply from elevated right-sided pressures 
(Goldhaber et al., 2003; Wood, 2002). 
The hemodynamic cascade provides an appreciation in understanding the roles the various 
imaging modalities and biomarkers play in the risk assessment of patients with acute PE. 
 
 
Fig. 1. Hemodynamic consequences due to acute pulmonary embolism and mechanism of 
biomarkers detection (PA, pulmonary artery; RV, right ventricle; LV, left ventricle; BNP, 
brain natriuretic peptide; NT-proBNP, NT-pro brain natriuretic peptide; H-FABP, heart-type 
fatty acid binding protein) 
3. Classification of risk 
The prognosis of acute PE correlates most directly with the degree of hemodynamic 
compromise and RV dysfunction. 
The European Society of Cardiology recommends an individual risk assessment of early PE-
related deaths (Torbicki et al, 2008). Based on the clinical presentation, presence of RV 
dysfunction and elevated biomarkers, high-risk PE has a short-term (in-hospital or 30-day) 
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mortality risk of > 15%. Non high-risk patients are more heterogenous and are further 
stratified into intermediate risk (short term mortality risk of 3 to 15%) and low risk (short 
term mortality risk of less than 1%) (Figure 2).  
 
 
Fig. 2. Risk stratification based on pulmonary embolism-related adverse outcomes 
4. Risk assessment based on clinical parameters and risk models 
The presence of co-morbidities increases the risk of adverse events, even with a small  
PE. Advanced age (more than 70 years old), congestive heart failure, cancer, or chronic  
lung disease were identified as independent predictors of 3-month mortality from PE 
(Goldhaber, 1999). 
The clinical manifestations of acute PE are non-specific and often overlap with other cardiac 
and pulmonary conditions. Chest pain is one of the most frequent presentations of PE. 
Pleuritic chest pain, with or without dyspnea, is usually caused by pleural irritation due to 
distal emboli which may be associated with pulmonary infarction. Individuals may also 
present with retrosternal angina-like chest pain, reflecting right ventricular ischemia. 
Isolated dyspnea of a rapid onset is suspicious of a more central and hemodynamically 
significant PE. Occasionally, the onset of dyspnea is more insidious especially in patients 
with co-existing heart failure or pulmonary disease.  
Cardiogenic shock occurs in less than 5% of acute PE, and these patients have a high risk of 
death. Conversely, patients with non-massive PE present with stable blood pressure and 
have a lower risk of death. In the International Cooperative Pulmonary Embolism Registry, 
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the death rate was about 58% in hemodynamically unstable patients and about 15% in 
patients who were hemodynamically stable (Goldhaber et al., 1999). 
Despite the limited sensitivity and specificity of individual symptoms, and signs, clinical 
risk models consisting of a combination of clinical variables makes it possible to identify 
patients with suspected PE into risk categories. The Geneva prognostic index and the 
Pulmonary Embolism Prognostic Index (PESI) are two standardized prognostic scores that 
incorporated systolic blood pressure, amongst other clinical parameters, to predict risk of 
PE-related adverse outcomes. These scores have been well validated to identify low-risk, 
clinically stable patients for outpatient treatment. 
The Geneva prognostic index is based mainly on findings from the past medical history and 
the clinical examination (Table 1). Risk stratification was performed using the score with a 
maximum of 8 points. Patients with a score of 2 or less are considered at low risk for PE-
related adverse events. Of the 180 low risk patients identified, only 4 experienced an adverse 
outcome at 3 months (Wicki et al., 2000). 
The PESI score uses 11 weighted clinical parameters commonly available on presentation 
(Table 2). Patients are stratified by their scores into five classes of increasing risk of death 
and adverse outcomes. Patients classified as low risk (score of 85 or less corresponding to 
PESI Class I or II) have a 30-day mortality of 1.0% (Aujesky et al., 2006).  
Of the two, the PESI score appears to be more accurate at predicting low-risk patients. In a 
head-to-head comparison, the two models were retrospectively applied in a cohort of 599 
patients with PE. The 30-day mortality in the Geneva low-risk patients was 5.6% compared 
to the PESI low-risk mortality rate of 0.9%. The PESI score classified fewer patients as low-
risk than the Geneva model (36% vs. 84%), but the area under the receiver operating curve 
was higher for the PESI (0.76 vs. 0.61) (Jiménez et al., 2007).  
Unfortunately, the major limitation of the PESI is the difficulty to apply in a busy clinical 
environment. There are many variables to be considered, each with its own weight. To 
address this limitation, a simplified PESI has been developed with similar prognostic 
accuracy (Jiménez et al., 2010). However, prospective validation of the simplified PESI is 
lacking. 
 
Risk Factor 
Geneva Risk Scale 
(Points) 
Active cancer 2 
Systolic blood pressure < 100mmHg 2 
Concomitant deep venous thrombosis 
at diagnosis 
1 
History of venous thromboembolism 1 
Congestive heart failure 1 
Hypoxia (arterial PaO2 < 60mmHg) 1 
Geneva Risk Categories 
Low risk: 2 or fewer points; High risk: 3 or more points 
Table 1. Geneva Pulmonary Embolism Prognostic Index 
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Variable Points 
Age 1 point/year 
Male gender 10 
Cancer 30 
Congestive heart failure 10 
Chronic lung disease 10 
Heart rate > 110/min 20 
Systolic blood pressure < 100mmHg 30 
Respiratory rate ≥ 30/min 20 
Body temperature < 36° 20 
Disorientation, lethargy, stupor or coma 60 
Oxygen saturation < 90%(pulsoximetry) 20 
 
Risk category Points 30-day mortality risk 
Class I < 65 0 % 
Class II 66 to 85 1.0 % 
Class III 86 to 105 3.1 % 
Class IV > 125 24.4 % 
Table 2. Pulmonary Embolism Severity index (Low risk = Class I and II) 
5. Risk assessment based on presence of right ventricular dysfunction 
The majority of patients with acute PE are stable at time of diagnosis, but this may not 
necessarily imply a benign course. Patients may appear stable initially because the 
development of RV failure and cardiogenic shock can be delayed as the vicious cycle of 
elevated pulmonary resistance, RV dilatation, and the RV hypokinesis unfolds. In stable 
patients with acute PE, the presence of RV dysfunction is associated with a high mortality 
rate (Sanchez et al., 2008).  
In addition, RV dysfunction in acute PE predicts recurrent thromboembolic events. During a 
mean follow-up of three years, patients with persistent RV dysfunction were more likely to 
have a recurrent PE, deep venous thrombosis or higher PE-related deaths compared with 
patients without RV dysfunction or had RV dysfunction that resolved at discharge (Grifoni 
et al., 2006).  
5.1 Echocardiography 
Echocardiography is non-invasive and able to provide very useful information promptly. 
However, it is not recommended as a routine imaging test to diagnose PE because an 
echocardiogram can appear normal in about 50% of the patients with suspected PE. Despite 
its limitations, a bedside echocardiogram in a hemodynamically unstable patient is an 
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invaluable first-line tool to diagnose other conditions that mimic an acute PE such as 
myocardial infarction, proximal aortic dissection or a pericardial tamponade. These 
emergency conditions require management very different from an acute PE.  
More importantly, the main role of echocardiography in the setting of an acute PE is to 
identify a sub-group of stable, non-high-risk patients with RV dysfunction for more 
aggressive management. The prognostic implications of RV dysfunction detected with 
echocardiography, even in stable acute PE patients, are clear and this has been illustrated in 
two separate meta-analyses. In all studies, patients with normal RV function have very good 
prognosis, with low in-hospital mortality (ten Wolde et al., 2004; Sanchez et al., 2008). 
Unfortunately, unlike the left ventricle, the anatomy of the RV is complex and assessment of 
RV function is challenging. Thus, the criteria of RV dysfunction are not well established and 
differ among published studies (Table 3).  
Echocardiography detects both direct and indirect hemodynamic consequences of acute PE 
(Figure 1). Direct evidence of RV dysfunction includes a dilated RV cavity as compared to 
the LV. More convincingly, the concomitant presence of RV hypokinesis suggests a failing 
RV. However, qualitative assessment of RV wall motion is subjective and insufficient in this 
era of standardization. There is a distinctive two-dimensional echocardiographic finding of 
regional RV dysfunction that has been described in acute PE. This abnormality is 
characterized by the presence of normal or hyperdynamic RV apex despite moderate to 
severe RV free-wall hypokinesis (McConnell sign, Figure 3). Echocardiography may also 
show flattened inter-ventricular septum or paradoxical motion towards the LV during 
systole to suggest RV pressure overload (Figure 4). 
 
 
Fig. 3. Apical four-chamber view demonstrating McConnell sign: hypokinesis of the right 
ventricle (RV) free wall sparing the apex (arrows). The RV is markedly dilated.  
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Authors Definition of RV dysfunction 
Goldhaber et al, 1993, 1999 
Ribeiro et al, 1997, 
Jerjes-Sanchz et al, 2001, 
Kucher et al, 2003, 2005 
RV hypokinesis by qualitative assessment of the RV wall 
motion 
Kasper et al, 1997 
Dilated RV cavity (qualitative assessment of RV compared 
to left ventricle) or RVEDD > 30mm; or when 2 of the 
following were present: 
1. TR velocity > 2.8m/s 
2. TR velocity > 2.5m/s in the absence of inspiratory 
collapse of the IVC 
3. Dilated RPA (> 12mm/m2) 
4. RV wall thickness > 5mm 
5. Loss of inspiratory collapse of the IVC 
Grifoni et al, 2000, 2001 
Presence of any 1 of the following:
1. Dilated RV (RVEDD/LVEDD > 1 or RVEDD > 
30mm) 
2. Septal dyskinesis 
3. Pulmonary hypertension (Doppler PAT <90ms or 
RV-RA gradient >30mmHg) 
4. Absence of RV hypertrophy (thickness > 7mm) 
Pieralli et al, 2006 
Presence of any 1 of the following:
1. Dilated RV (RVEDD/LVEDD > 1 or RVEDD > 
30mm) 
2. Septal dyskinesis 
3. Pulmonary hypertension (Doppler PAT <90ms or 
RV-RA gradient >30mmHg)
Vieillar-Baron et al, 2001 RVEDA/LVEDA > 0.6 with septal dyskinesis 
Kostrubiec et al, 2005 
Presence of any 1 of the following: 
1. RVEDD/LVEDD > 0.6 with RV hypokinesis 
2. Pulmonary hypertension (Elevated TVPG >30mmHg 
with PAT <80ms) 
(RVEDD/LVEDD, right to left end-diastolic diameter ratio; RVEDA/LVEDA, right to left ventricular 
end-diastolic area ratio; RV-RA gradient, right ventricular-right atrial gradient; PAT, pulmonary arterial 
flow acceleration time; TVPG, tricuspid valve pressure gradient; IVC, inferior vena cava; TR, tricuspid 
regurgitation). 
Table 3. Studies evaluating RV dysfunction with echocardiography  
Indirect evidence of RV dysfunction from echocardiography includes raised pulmonary 
artery systolic pressure (PASP). This can be estimated from the right ventricular systolic 
pressure (RVSP) according to the formula: PASP = RVSP + estimated right atrial pressure 
(Figure 5). The RVSP is obtained from the velocity of the tricuspid regurgitant jet (v), such 
that RVSP = 4v2 and the right atrial pressure is estimated from the size and respiratory 
variation of the inferior vena cava.  
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Fig. 4. Parasternal short axis view showing an enlarged right ventricle (RV) with a “D” 
shaped septum, suggesting RV pressure overload. 
 
 
Fig. 5. Continuous wave Doppler demonstrating peak tricuspid velocity of 3.2m/s, 
corresponding to a right ventricular systolic pressure of 41mmHg.  
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An elevated pulmonary artery systolic pressure of more than 50mmHg at time of diagnosis 
is associated with persistent pulmonary hypertension at 1 year (Ribeiro et al., 1999). In 
patients with acute PE, the absence of any significant tricuspid regurgitation makes the 
severe pulmonary hypertension less likely. 
Besides the evidence of RV dysfunction and elevated pulmonary arterial pressures, other 
echocardiographic features with prognostic implications include:  
1. A right-to-left shunt, such as a patent foramen ovale (PFO). In a prospective study of 
139 consecutive patients with acute PE, PFO was diagnosed in 48 patients by contrast 
echocardiography. Evidence of a PFO in patients with acute PE was associated with 
higher mortality rate (33% vs. 14%) and higher incidence of peripheral thromboembolic 
events (Konstantinides et al., 1998). These patients are particularly prone to paradoxical 
embolism due to increased right-to-left shunt from elevated right-sided pressures. 
2. A free-floating right heart thrombus (Figure 6). The prevalence of patients with a right 
heart thrombus visualized during echocardiography was about 4% (Torbicki et al., 
2003). Thrombus from the right heart usually arises from the lower limb veins. These 
thrombi are highly mobile and often described as having the appearance of a worm, or 
snake. Free-floating thrombus can embolize at any time and have a dismal prognosis 
regardless of therapeutic option (Chin et al., 2010). The mortality rate of about 20% 
within 24 hours of diagnosis, and mortality is significantly linked with the occurrence 
of cardiac arrest (Chartir et al., 1999).  
5.2 Computed tomography 
Contrast enhanced computer tomography (CT) of the pulmonary arteries is increasingly 
used as a first-line imaging modality for PE diagnosis. The anatomical distribution and 
burden of embolic occlusion of the pulmonary arterial bed can be assessed easily by CT 
(Figure 7). However, the anatomical assessment seems less relevant for risk stratification 
than assessment based on functional (hemodynamic) consequences of PE. 
Most scanners allow reconstruction of standardized cardiac views and direct measurements 
of ventricular dimensions can be made. RV enlargement based on RV-to-LV dimension 
ratio, RVd/LVd, (Figure 8) on the reconstructed CT four-chamber view correlated with RV 
dysfunction on echocardiogram. Using RVd/LVd > 0.9 as cut-off, the sensitivity and 
specificity for predicting PE-related adverse events were 83% and 49% on the reconstructed 
CT, respectively. Comparatively, the sensitivity and specificity of RVd/LVd >0.9 on 
echocardiography were 71% and 56%, respectively (Quiroz et al., 2004).  
In addition to having good correlation with RV dysfunction on echocardiography, assessment 
of RV enlargement on chest CT in acute PE also predicted patients at risk of death from RV 
failure (Van der Meer et al., 2005; Schoepf et al., 2004). The greatest role appears to be the 
identification of low-risk patients due to its high negative predictive value (Table 4).  
 
Author 
CT equipment 
(Cutoff) 
Sensitivity 
(%) 
Specificity 
(%) 
NPV 
(%) 
PPV 
(%) 
Van der Meer et 
al., 2005 
SDCT 
(RV/LV >1) 
100 45 100 10 
Schoepf et al., 
2004 
4 – 16 MDCT 
(RV/LV > 0.9) 
78 38 92 16 
Table 4. Trials reporting RV/LV diameter ratio assessed by CT as a risk marker for 30-day 
all cause mortality in acute pulmonary embolism. 
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Fig. 6. Free floating thrombus (red arrow) transiting from the RA causing acute pulmonary 
embolism (RA, right atrium; LA, left atrium; LV, left ventricle). 
Other CT-derived parameters have also been investigated. The presence of interventricular 
septal bowing is predictive of PE-related deaths but has low sensitivity and high inter-
observer variability (Araoz et al., 2007), scores to quantify the extent and location of 
pulmonary artery obstruction have been developed but not shown to be of prognostic 
relevance yet (Qanadil et al., 2001; Ghanima et al., 2007).  
5.3 Ventilation-perfusion scintigraphy 
Lung ventilation-perfusion scintigraphy (V/Q scan) is a well-established diagnostic test 
used in patients suspected of PE. Interpretation of the scans can vary, depending on the 
algorithms used (PIOPED criteria, modified PIOPED criteria, McMaster Clinical criteria and 
PisaPED criteria) and the experience of the reader. The diagnostic roles and limitations of 
V/Q scan are beyond the scope and will not be discussed in this chapter. 
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Fig. 7. Computed tomography pulmonary angiogram showing a large embolus within the 
right main pulmonary artery, extending to the main right upper lobe. 
 
 
Fig. 8. Measurement of the short axes of the RV (47 mm) and LV (39 mm) on computed 
tomography pulmonary angiogram of the same patient (RV, right ventricle; LV, left 
ventricle) 
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Perfusion defects due to PE increase with the number and size of emboli, without 
corresponding ventilation compromise (“mismatch” defects). However, the prognostic 
implications of the number and size of defects on a V/Q scan have not been investigated.  
6. Risk assessment based on biomarkers of myocardial injury 
Cardiac troponins I and T as well as NT-pro brain natriuretic peptide (NT-proBNP) and 
brain natriuretic peptide (BNP) have emerged as promising tools for risk stratification. 
6.1 Cardiac troponins  
Cardiac troponins may be increased in patients with PE, even in the absence of coronary 
artery disease. The presumed mechanism is acute right heart overload attributed to 
myocardial ischemia and from oxygen supply-demand mismatch. The elevation usually 
resolves within 40 hours following PE in contrast to more prolonged elevation after an acute 
myocardial infarction. The peak level is usually lower than in acute myocardial infarction 
(Müller-Bardorff et al., 2002). 
Patients with an elevated troponin I or troponin T levels had an increased risk for short-term 
mortality (OR 5.24, 95% CI 3.28 – 8.38) or PE-related deaths (OR 9.44, 95% CI 4.14 – 21.49). 
Elevated troponin levels even among patients who are hemodynamically stable are 
associated with higher mortality (Becattini et al., 2007; Jimenez et al., 2008). 
Irrespective of various methods and cut-off values applied, most trials reported a low 
positive predictive value for PE-related mortality in the range of 12% to 44%, but with a very 
high negative predictive value between 99% and 100%. 
6.2 Brain natriuretic peptide 
Right ventricular dysfunction is associated with increased myocardial stretch which leads to 
the release of BNP and its amino terminal portion, NT-proBNP.  
In acute PE, increasing levels of BNP or NT-proBNP predict the severity of RV dysfunction 
and mortality (Cavallazzi et al., 2008; Klok et al., 2008; Lega et al., 2009). Although elevated 
concentrations are related to worse outcome, the positive predictive value is low. On the 
other hand, low levels of BNP or NT-proBNP can be used reliably to identify patients with a 
good prognosis (Table 5).  
6.3 Novel biomarker 
Heart-type fatty acid binding protein (H-FABP), a protein released earlier than troponins 
during myocardial ischemia, has been evaluated as a prognostic marker in acute PE. The 
studies have reported a high sensitivity (78% to 100%) and negative predictive value (96% to 
100%), but these studies are small and such measurements are not widely available (Puls et 
al., 2007; Kaczynska et al., 2006). 
6.4 Summary of evidence on the prognostic value of biomarkers 
Many studies did not perform an extensive comparison between all the available 
biomarkers, thus it remains debatable which biomarker will yield the best prognostic value. 
Another limitation is biomarker thresholds were determined retrospectively, thus no 
consistent cut-off values were used in the studies. Despite this, it appears BNP/NT-proBNP 
and cardiac troponins could be used as rule-out tests. 
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Author 
Test used 
(Threshold) 
Outcome 
Definition 
Sensitivity
(%) 
Specificity 
(%) 
NPV 
(%) 
PPV 
(%) 
Ten Wolde et al, 
2003 
BNP 
Shionoriaa 
(21.7 
pmol/L) 
PE-related 
deaths 
86 71 99 17 
Kucher et al, 
2003a 
NT-proBNPb 
(500 pg/mL) 
In-hospital 
death or 
adverse 
eventse 
95 57 97 45 
Kucher et al, 
2003b 
BNP Triagec 
(50 pg/mL) 
In-hospital 
death or 
adverse 
eventse 
95 60 97 48 
Pruszczyk et al, 
2003 
NT-proBNPb 
(600 pg/mL) 
In-hospital 
mortality 
100 33 100 23 
Binder et al, 
2005 
NT-proBNPb 
(1000 
pg/mL) 
In-hospital 
mortality 
100 49 100 10 
Kostrubiec et al, 
2007 
NT-proBNPb 
(7500 
pg/mL) 
30-day all 
cause 
mortality 
65 93 94 61 
(a-cTests used: aShionoria, CIS Bio International; bElecsys, Roche Diagnostics; cTriage, Biosite 
Technologies. eAdverse events include the need for resuscitation, mechanical ventilation, inotropic 
support, thrombolytics, or embolectomy) 
Table 5. Prognostic value of BNP or NT-proBNP in acute pulmonary embolism  
Due to the high negative predictive value for PE-related mortality and adverse events, a 
potential approach consists of a combination of biomarker testing and echocardiography. In 
the setting of an acute PE, further risk stratification with echocardiography is warranted in 
patients with elevated cardiac biomarkers due to limited specificity of the assays for 
predicting RV dysfunction. Conversely, in patients with levels below cut-off, 
echocardiography will likely not add prognostic information.  
This approach was demonstrated in a prospective study of 124 patients diagnosed with 
acute PE. The presence of RV dysfunction on echocardiography in patients with elevated 
NT-proBNP (cut-off of 1000 pg/mL) or cardiac troponins (cut-off of 0.04 ng/mL) is 
associated with a 10-fold increase in complication risk compared with patients biomarker 
levels below threshold (Binder et al., 2005).  
7. Risk of recurrence 
Recurrent PE can occur despite adequate anticoagulation therapy in patients who had 
survived an acute PE.  
Patients with unprovoked PE (PE occurring in the absence of established risk factors or 
predisposing illnesses) are at a higher risk for recurrent PE compared to patients with risk 
factors for PE. In contrast, patients with risk factors of PE have a higher mortality risk (Klok 
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et al., 2010). In addition, patients who presented with a first symptomatic PE are at a 4-fold 
increased risk of recurrent symptomatic PE compared to patients who presented with deep 
venous thrombosis without symptoms of PE (Eichinger et al., 2004).  
In patients with recurrent PE or progressive deep venous thrombosis (DVT) despite 
adequate anticoagulation therapy, inferior vena cava (IVC) filters may be indicated. IVC 
filter placement is generally accepted in patients with massive PE or limited 
cardiopulmonary reserve and DVT. Current evidence indicates that IVC filters are largely 
effective, with breakthrough PE occurring in only 0% to 6.2% cases. Recurrent PE, IVC 
thrombosis, filter migration, filter fracture, or penetration of caval wall can sometimes occur 
with long-term use (Chung et al., 2008). 
8. Conclusion 
Risk stratification of acute PE is fundamental not only to select an appropriate treatment 
strategy, but also to potentially reduce costs of management (Figure 2). An appropriate risk 
stratification algorithm would include clinical, imaging and biomarkers. High risk PE is 
diagnosed in the presence of shock or persistent hypotension and should warrant urgent 
management. Thrombolysis with alteplase (rtPA), streptokinase, or urokinase is the 
recommended therapy. Embolectomy could represent an alternative therapy for patients 
with shock in the acute setting when thrombolysis has been unsuccessful.  
Hemodynamically stable patients without RV dysfunction or myocardial injury are at low-
risk for PE-related adverse events. These patients may be eligible for early hospital 
discharge or even outpatient treatment.  
In the remaining normotensive patients, a plausible strategy is to combine biomarkers with 
echocardiography. The presence of RV dysfunction and myocardial injury identifies patients 
at intermediate risk.  
Whether intermediate risk patients will have any survival benefit with early initiation of 
reperfusion therapy (and what type of therapy) is not well accepted. Current 
recommendations proposed thrombolysis be instituted in selected patients at high risk for 
adverse events without contraindications (Grade IIB ESC and ACCP VIII Edition), and 
intravenous unfractionated heparin should be reserved to conditions in which thrombolysis 
is contraindicated (Grade IA ESC and ACCP VIII Edition). An ongoing study assessing the 
benefit of thrombolysis as compared with anticoagulation in hemodynamically stable 
patients with evidence of RV dysfunction and an elevated troponin levels will hopefully 
provide some insights (NCT00639743). 
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